Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury

Conditions

Pulmonary Arterial Hypertension
Pulmonary Hypertension

Interventions

DRUG: Sitaxsentan
DRUG: Sitaxsentan and Sildenafil

Sponsor

Pfizer